Skip to content

Impact of Advance Care Planning on Care for Patients With Advanced Heart Failure

Impact of Advance Care Planning on Care for Patients With Advanced Heart Failure: A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02299180
Enrollment
282
Registered
2014-11-24
Start date
2015-02-28
Completion date
2018-06-30
Last updated
2019-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Advanced care planning, End of life care

Brief summary

Aims: Advance care planning (ACP) is considered to be one of the most promising interventions to enable patients with life limiting illnesses to receive treatment at the end of life (EOL) according to their own preferences and to promote EOL conversations between patients and their health care providers. Through a 2-arm randomized controlled trial (RCT) of patients with Class III and IV heart failure (New York Heart Association Functional Classification), we propose to assess: 1. Whether patients in the ACP arm have a greater likelihood of receiving EOL care consistent with their preferences as stated in the latter of the last ACP document or the last patient interview, compared to patients in the control arm. 2. Heath care costs during study duration between patients in ACP and control arms. 3. Patient's understanding of own illness and their participation in decision making between the ACP and control arms. 4. Patient's quality of life, anxiety and depression between ACP and control arms. Methodology: A total of 254 patients with advance heart failure will be randomized to receive intervention (ACP arm; N=127) or usual care (control arm; N=127). The RCT will be conducted at the National Heart Centre and Singapore General Hospital. Patients in both arms will be followed for one year or till death, whichever is earlier, and interviewed every 4 months during this duration. Clinical Significance: If benefits of ACP are shown to add value through this trial, then this study will help to promote acceptance of ACP among patients and health care providers across Singapore and elsewhere.

Interventions

BEHAVIORALACP

Sponsors

National Heart Centre Singapore
CollaboratorOTHER
Singapore General Hospital
CollaboratorOTHER
Duke-NUS Graduate Medical School
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patient participant: * Patients must be 21 years old or older and must be diagnosed with advanced heart failure (New York Heart Association Class III and IV). Patients must be aware of their diagnosis * Caregiver/Decision-maker participant: Subject must be 21 years old or older Participant must be either * appointed substitute decision maker or * most likely to be substitute decision maker for patient (if patient were to lose decision-making capacity)

Exclusion criteria

* Patient participant: Patients must not have any psychiatric or cognitive disorders * Caregiver/Decision-maker participant: Cannot be a maid or foreign domestic worker

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients receiving end of life care consistent with their stated preferencesone yearPatient's stated preferences for cardiopulmonary resuscitation (CPR) and life prolonging treatments (e.g. mechanical ventilation, dialysis, feeding tube, intravenous antibiotics, blood transfusion) will be assessed from their last survey or their ACP document. The actual treatment received by the patient will be assessed from medical records after the patient's death. Proportion of patients who died and received treatment consistent with their stated preferences will be calculated and compared between ACP and control arms

Secondary

MeasureTime frameDescription
Total health care expenditure of patients during study durationone yearTotal healthcare expenditures during the study duration will be assessed from institutional databases and compared between ACP and control arms.
Patient scores for Quality of lifeevery four months for one yearQuality of life will be assessed through McGill Quality of Life scale and compared between ACP and control arms.
Patient's understanding of own illnessevery four months for one yearPatient's understanding of own prognosis will be assessed and compared between ACP and control arms.
Patient scores for anxiety and depressionevery four months for one yearPatient's anxiety and depression will be assessed through Hospital Anxiety and Depression scale and scores will be compared between ACP and control arms.
Patient's participation in decision-makingevery four months for one yearPatient scores on decision conflict scale will be assessed and compared between ACP and control arms.

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026